Literature DB >> 22736432

Comprehensive functional assessment of MLH1 variants of unknown significance.

Ester Borràs1, Marta Pineda, Angela Brieger, Inga Hinrichsen, Carolina Gómez, Matilde Navarro, Judit Balmaña, Teresa Ramón y Cajal, Asunción Torres, Joan Brunet, Ignacio Blanco, Guido Plotz, Conxi Lázaro, Gabriel Capellá.   

Abstract

Lynch syndrome is associated with germline mutations in DNA mismatch repair (MMR) genes. Up to 30% of DNA changes found are variants of unknown significance (VUS). Our aim was to assess the pathogenicity of eight MLH1 VUS identified in patients suspected of Lynch syndrome. All of them are novel or not previously characterized. For their classification, we followed a strategy that integrates family history, tumor pathology, and control frequency data with a variety of in silico and in vitro analyses at RNA and protein level, such as MMR assay, MLH1 and PMS2 expression, and subcellular localization. Five MLH1 VUS were classified as pathogenic: c.[248G>T(;)306G>C], c.[780C>G;788A>C], and c.791-7T>A affected mRNA processing, whereas c.218T>C (p.L73P) and c.244A>G [corrected] (p.T82A) impaired MMR activity. Two other VUS were considered likely neutral: the silent c.702G>A variant did not affect mRNA processing or stability, and c.974G>A (p.R325Q) did not influence MMR function. In contrast, variant c.25C>T (p.R9W) could not be classified, as it associated with intermediate levels of MMR activity. Comprehensive functional assessment of MLH1 variants was useful in their classification and became relevant in the diagnosis and genetic counseling of carrier families.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736432     DOI: 10.1002/humu.22142

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  10 in total

1.  Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes.

Authors:  Monika Morak; Kerstin Schaefer; Verena Steinke-Lange; Udo Koehler; Susanne Keinath; Trisari Massdorf; Brigitte Mauracher; Nils Rahner; Jessica Bailey; Christiane Kling; Tanja Haeusser; Andreas Laner; Elke Holinski-Feder
Journal:  Eur J Hum Genet       Date:  2019-07-22       Impact factor: 4.246

2.  Classifying MMR variants: time for revised nomenclature in Lynch syndrome.

Authors:  Y Nancy You; Eduardo Vilar
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

Review 3.  Genetic predisposition to colorectal cancer: where we stand and future perspectives.

Authors:  Laura Valle
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  The changing landscape of Lynch syndrome due to PMS2 mutations.

Authors:  J Blount; A Prakash
Journal:  Clin Genet       Date:  2018-03-15       Impact factor: 4.438

5.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

6.  In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation.

Authors:  Ester Borras; Kyle Chang; Mala Pande; Amanda Cuddy; Jennifer L Bosch; Sarah A Bannon; Maureen E Mork; Miguel A Rodriguez-Bigas; Melissa W Taggart; Patrick M Lynch; Y Nancy You; Eduardo Vilar
Journal:  Cancer Prev Res (Phila)       Date:  2017-08-01

7.  Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.

Authors:  Felipe Carneiro da Silva; José Roberto de Oliveira Ferreira; Giovana Tardin Torrezan; Márcia Cristina Pena Figueiredo; Érika Maria Monteiro Santos; Wilson Toshihiko Nakagawa; Rafael Canfield Brianese; Ligia Petrolini de Oliveira; Maria Dirlei Begnani; Samuel Aguiar-Junior; Benedito Mauro Rossi; Fábio de Oliveira Ferreira; Dirce Maria Carraro
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

8.  Scarce evidence of the causal role of germline mutations in UNC5C in hereditary colorectal cancer and polyposis.

Authors:  Pilar Mur; Elena Sánchez-Cuartielles; Susanna Aussó; Gemma Aiza; Rafael Valdés-Mas; Marta Pineda; Matilde Navarro; Joan Brunet; Miguel Urioste; Conxi Lázaro; Victor Moreno; Gabriel Capellá; Xose S Puente; Laura Valle
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

9.  Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.

Authors:  Tyler Landrith; Bing Li; Ashley A Cass; Blair R Conner; Holly LaDuca; Danielle B McKenna; Kara N Maxwell; Susan Domchek; Nichole A Morman; Christopher Heinlen; Deborah Wham; Cathryn Koptiuch; Jennie Vagher; Ragene Rivera; Ann Bunnell; Gayle Patel; Jennifer L Geurts; Morgan M Depas; Shraddha Gaonkar; Sara Pirzadeh-Miller; Rebekah Krukenberg; Meredith Seidel; Robert Pilarski; Meagan Farmer; Khateriaa Pyrtel; Kara Milliron; John Lee; Elizabeth Hoodfar; Deepika Nathan; Amanda C Ganzak; Sitao Wu; Huy Vuong; Dong Xu; Aarani Arulmoli; Melissa Parra; Lily Hoang; Bhuvan Molparia; Michele Fennessy; Susanne Fox; Sinead Charpentier; Julia Burdette; Tina Pesaran; Jessica Profato; Brandon Smith; Ginger Haynes; Emily Dalton; Joy Rae-Radecki Crandall; Ruth Baxter; Hsiao-Mei Lu; Brigette Tippin-Davis; Aaron Elliott; Elizabeth Chao; Rachid Karam
Journal:  NPJ Precis Oncol       Date:  2020-02-24

10.  Splicing analyses for variants in MMR genes: best practice recommendations from the European Mismatch Repair Working Group.

Authors:  Monika Morak; Marta Pineda; Alexandra Martins; Pascaline Gaildrat; Hélène Tubeuf; Aurélie Drouet; Carolina Gómez; Estela Dámaso; Kerstin Schaefer; Verena Steinke-Lange; Udo Koehler; Andreas Laner; Julie Hauchard; Karine Chauris; Elke Holinski-Feder; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2022-06-09       Impact factor: 5.351

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.